IN8bio (INAB) Stock Forecast, Price Target & Predictions
INAB Stock Forecast
IN8bio stock forecast is as follows: a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
INAB Analyst Ratings
According to 2 Wall Street analysts, IN8bio's rating consensus is 'Buy'. The analyst rating breakdown for INAB stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 03, 2024 | Laidlaw | Buy | Buy | Hold |
| Aug 30, 2022 | H.C. Wainwright | - | Buy | Initialise |
IN8bio's last stock rating was published by Laidlaw on Jun 03, 2024. The company gave INAB a "Buy" rating, the same as its previous rate.
IN8bio Financial Forecast
IN8bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | $16.00M | $5.80M | - | - | - | - | - |
| High Forecast | $16.00M | $5.80M | - | - | - | - | - |
| Low Forecast | $16.00M | $5.80M | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
IN8bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. INAB's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
IN8bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict INAB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than IN8bio's previous annual EBITDA (undefined) of $NaN.
IN8bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-4.06M | $-3.84M | $-4.29M | $-4.29M | $-5.49M | $-6.99M | $-7.82M |
| High Forecast | $-4.06M | $-3.84M | $-4.29M | $-4.29M | $-5.49M | $-5.92M | $-7.82M |
| Low Forecast | $-4.06M | $-3.84M | $-4.29M | $-4.29M | $-5.49M | $-7.53M | $-7.82M |
| Surprise % | - | - | - | - | - | - | - |
IN8bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. INAB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
IN8bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
IN8bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to INAB last annual SG&A of $NaN (undefined).
IN8bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.09 | $-0.09 | $-0.10 | $-0.10 | $-0.12 | $-0.15 | $-0.17 |
| High Forecast | $-0.09 | $-0.09 | $-0.10 | $-0.10 | $-0.12 | $-0.13 | $-0.17 |
| Low Forecast | $-0.09 | $-0.09 | $-0.10 | $-0.10 | $-0.12 | $-0.17 | $-0.17 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, IN8bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to INAB previous annual EPS of $NaN (undefined).
IN8bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INAB | IN8bio | $0.32 | $14.00 | 4275.00% | Buy |
| CUE | Cue Biopharma | $0.59 | $5.00 | 747.46% | Buy |
| RVPH | Reviva Pharmaceuticals | $1.20 | $10.00 | 733.33% | Buy |
| PYPD | PolyPid | $3.47 | $25.00 | 620.46% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| GANX | Gain Therapeutics | $1.47 | $7.00 | 376.19% | Buy |
| INMB | INmune Bio | $5.46 | $22.00 | 302.93% | Buy |
| CNSP | CNS Pharmaceuticals | $0.15 | $0.50 | 233.33% | - |
| WVE | Wave Life Sciences | $5.86 | $14.00 | 138.91% | Buy |
| ANIX | Anixa Biosciences | $3.35 | $8.00 | 138.81% | Buy |
| ANNX | Annexon | $7.20 | $14.00 | 94.44% | Buy |
| ZURA | Zura Bio | $3.70 | $5.00 | 35.14% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
| PALI | Palisade Bio | $3.79 | $1.50 | -60.42% | Buy |
INAB Forecast FAQ
Is IN8bio a good buy?
Yes, according to 2 Wall Street analysts, IN8bio (INAB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of INAB's total ratings.
What are IN8bio's analysts' financial forecasts?
IN8bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-20.307M (high $-19.23M, low $-20.845M), average SG&A $0 (high $0, low $0), and average EPS is $-0.45 (high $-0.426, low $-0.462). INAB's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $21.8M (high $21.8M, low $21.8M), average EBITDA is $0 (high $0, low $0), average net income is $-16.471M (high $-16.471M, low $-16.471M), average SG&A $0 (high $0, low $0), and average EPS is $-0.365 (high $-0.365, low $-0.365).